The Crohn's-disease-susceptibility protein, NOD2, coordinates signaling responses upon intracellular exposure to bacteria [1] [2] [3] [4] [5] [6] . Although NOD2 is known to activate NFkB, little is known about the molecular mechanisms by which NOD2 coordinates functionally separate signaling pathways such as NFkB, JNK, and p38 to regulate cytokine responses [3] [4] [5] [6] . Given that one of the characteristics of Crohn's disease is an altered cytokine response to normal bacterial flora [1, 2] , the coupling of signaling pathways could be important for Crohn's-disease pathophysiology. We find that a MAP3K, MEKK4, binds to RIP2 to sequester RIP2 from the NOD2 signaling pathway. This MEKK4:RIP2 complex dissociates upon exposure to the NOD2 agonist, MDP, allowing NOD2 to bind to RIP2 and activate NFkB. MEKK4 thus sequesters RIP2 to inhibit the NOD2:RIP2 complex from activating NFkB signaling pathways, and Crohn's-disease-associated NOD2 polymorphisms cannot compete with MEKK4 for RIP2 binding. Lastly, we find that MEKK4 helps dictate signal specificity downstream of NOD2 activation as knockdown of MEKK4 in macrophages exposed to MDP causes increased NFkB activity, absent p38 activity, and hyporesponsiveness to TLR2 and TLR4 agonists. These biochemical findings suggest that basal inhibition of the NOD2-driven NFkB pathway by MEKK4 could be important in the pathogenesis of Crohn's disease.
The Crohn's-disease-susceptibility protein, NOD2, coordinates signaling responses upon intracellular exposure to bacteria [1] [2] [3] [4] [5] [6] . Although NOD2 is known to activate NFkB, little is known about the molecular mechanisms by which NOD2 coordinates functionally separate signaling pathways such as NFkB, JNK, and p38 to regulate cytokine responses [3] [4] [5] [6] . Given that one of the characteristics of Crohn's disease is an altered cytokine response to normal bacterial flora [1, 2] , the coupling of signaling pathways could be important for Crohn's-disease pathophysiology. We find that a MAP3K, MEKK4, binds to RIP2 to sequester RIP2 from the NOD2 signaling pathway. This MEKK4:RIP2 complex dissociates upon exposure to the NOD2 agonist, MDP, allowing NOD2 to bind to RIP2 and activate NFkB. MEKK4 thus sequesters RIP2 to inhibit the NOD2:RIP2 complex from activating NFkB signaling pathways, and Crohn's-disease-associated NOD2 polymorphisms cannot compete with MEKK4 for RIP2 binding. Lastly, we find that MEKK4 helps dictate signal specificity downstream of NOD2 activation as knockdown of MEKK4 in macrophages exposed to MDP causes increased NFkB activity, absent p38 activity, and hyporesponsiveness to TLR2 and TLR4 agonists. These biochemical findings suggest that basal inhibition of the NOD2-driven NFkB pathway by MEKK4 could be important in the pathogenesis of Crohn's disease.
Results

MEKK4 Binds to and Sequesters RIP2
MAP3K7 (TAK1) binds to RIP2 and is responsible for NFkB activation downstream of the NOD2:RIP2 complex [7] [8] [9] , suggesting that the MAP3Ks help coordinate NOD2 signaling. For this reason, we screened a number of other MAP3Ks for binding to RIP2. As an example of the screening strategy, HEK293 cells were transfected with Omni-tagged RIP2 and HA-tagged MEKK2, MEKK3, or MEKK4. The MAP3Ks were immunoprecipitated, and the binding of the immunoprecipitated MAP3K to RIP2 was assayed by Western blot ( Figure 1A ). Of the MAP3Ks tested, only MEKK4 bound to RIP2 ( Figure 1A) . Cotransfection of CFP-tagged RIP2 and YFP-tagged MEKK4, followed by confocal microscopy, showed that RIP2 and MEKK4 colocalize within the cell ( Figure 1B ; individual localization of both the CFP-tagged RIP2 and the YPF-tagged MEKK4 are shown in Figure S1 , available online). We next sought to determine whether RIP2 could bind endogenous MEKK4 and to determine the effect of the NOD2 agonist MDP [10, 11] on this interaction. RAW 264.7 cells were treated with MDP for 0, 30, 60, or 90 min. Lysates were generated and MEKK4 was immunoprecipitated. Western blotting showed that in the unstimulated state, MEKK4 bound to RIP2 ( Figure 1C ). As MDP activates NFkB (as shown by phosphoIkBa blot, bottom panel Figure 1C ), the MEKK4:RIP2 complex dissociates ( Figure 1C ), and this was present in reciprocal coimmunoprecipitations ( Figure 1C) . Lastly, upon MDP stimulation, there was a fraction of MEKK4 that had slower mobility on SDS-PAGE. This appears to be a RIP2-dependent posttranslational modification on MEKK4 and will be detailed in subsequent work.
Because MDP stimulates RIP2's binding to NOD2, these findings suggest that the intracellular presence of MDP causes RIP2 to dissociate from MEKK4 and bind to NOD2 to cause NFkB activation. For testing this in a more controlled environment, HEK293 cells were transfected with MEKK4, RIP2, and/ or NOD2 in either the absence (Figures 2A and 2B ) or the presence ( Figures 2C and 2D ) of MDP, and the binding complexes were assayed. In the absence of MDP, MEKK4 competed RIP2 from NOD2 (Figures 2A and 2B) , whereas in the presence of MDP, NOD2 was able to compete RIP2 from MEKK4 (Figures 2C and 2D, Figure S2B ). MDP exposure in the absence of NOD2 had no effect on the MEKK4:RIP2 complex ( Figure S2A ). These data imply that cellular MDP exposure improves the binding of NOD2 to RIP2 such that RIP2 dissociates from MEKK4. Next, for determination of whether MEKK4 and NOD2 competed for the same region of RIP2, a deletion mutant of RIP2 that lacked the CARD domain was generated. This deletion mutant retained the ability to bind MEKK4 ( Figure S3B ) but lost the ability to bind to NOD2 ( Figure S3C ), suggesting that separate regions of RIP2 were responsible for binding MEKK4 and NOD2. Lastly, for determination of whether two different classes of Crohn's-disease-associated NOD2 polymorphisms were able to compete RIP2 from MEKK4 in the presence of MDP, cotransfection experiments were performed with the use of either the loss-of-function L1007insC NOD2 allele or the dominant negative, ulcerativecolitis-like Crohn's-disease NOD2 mutant (D291N). Wild-type (WT) NOD2, L1007insC, and D291N could not compete with MEKK4 in the absence of MDP ( Figure 2E ). Although WT NOD2 could compete with MEKK4 for RIP2 binding in the presence of MDP, L1007insC and D291N NOD2 could not compete with MEKK4 for RIP2 binding when MDP was present ( Figure 2F ), consistent with these susceptibility proteins' inability to fully activate NFkB after MDP stimulation [3, 5, 6 ].
MEKK4's Sequestration of RIP2 Inhibits NOD2-Induced NFkB Signaling These findings imply that MEKK4 may sequester RIP2 to inhibit NOD2-directed signaling. For determining the functionality of the MEKK4:RIP2 interaction, the kinase-dead versions of the MAP3Ks were assayed for their ability to inhibit RIP2-induced NEMO ubiquitination. Because the NOD2:RIP2 complex strongly stimulates the K63-linked polyubiquitination of the IKK scaffolding protein NEMO, polyubiquitination of NEMO can assay for RIP2's activation of the NFkB signaling *Correspondence: dwa4@case.edu pathway [8, 12, 13] . RIP2 was transfected into the cell with HAtagged ubiquitin and myc-tagged K399R NEMO. The K399R NEMO mutant was utilized, because this decreases basal NEMO ubiquitination and more readily assays for the ubiquitination site induced by RIP2 (K285) [13] . These ubiquitination experiments were performed under high-stringency conditions (0.25% SDS, 1 M NaCl) for reducing the possibility of artifactually assaying ubiquitinated NEMO binding proteins. Of the MAP3Ks tested, only MEKK4 and TAK1 were able to inhibit RIP2-induced NEMO ubiquitination, and kinase-dead MEKK4 inhibited this process much better than did kinasedead TAK1 ( Figure 3A ). For determining whether this effect was dependent on the kinase activity of MEKK4, WT MEKK4 was used in a similar experiment. WT MEKK4 inhibited RIP2-induced NEMO ubiquitination to the same extent as did kinase-dead MEKK4 ( Figure 3B ). Thus, consistent with the sequestration model, the kinase activity of MEKK4 is not required for inhibition of RIP2-induced NEMO ubiquitination.
Because MEKK4 strongly inhibited NEMO ubiquitination, MEKK4 binding to RIP2 could be a mechanism for inhibiting basal NOD2:RIP2-induced NFkB activity. For testing this and determining the effect of MEKK4 on other NOD2:RIP2-stimulated pathways [14] [15] [16] [17] [18] , cells were transfected with GSTIKKb ( Figure 3C ), IkBa ( Figure 3D ), FLAG-JNK ( Figure 3E ), or FLAG-p38 ( Figure 3F ) in the presence or absence of MEKK4 or RIP2. Activation of these proteins was assayed by Western blot with phospho-specific antibodies. MEKK4's inhibitory effect was specific for the NFkB pathway, because expression of MEKK4 strongly inhibited both RIP2-induced IKK activation and RIP2-induced IkBa phosphoryation ( Figures 3C and 3D ). MEKK4 did not affect RIP2's activation of JNK ( Figure 3E ), and RIP2 overexpression did not affect MEKK4's activation (B) For determining whether RIP2 and MEKK4 colocalized in the cell, CFP-RIP2 and YFP-MEKK4 fusion constructs were generated. 293 cells were transfected, and confocal microscopy was performed. In the basal, unstimulated state, RIP2 and MEKK4 colocalized. Multiple views with merging of the images are shown. (C) For determining whether endogenous RIP2 and MEKK4 bound one another and whether this complex persists in response to NOD2 activation (via MDP exposure), RAW 264.7 cells were stimulated with 20 mg/mL MDP for 0, 30, 60, or 90 minutes. Cells were lysed and subjected to immunoprecipitation with anti-MEKK4 or anti-RIP2. Western blotting was performed after extensive washing of the immunoprecipitate. As a control for MDP activation, lysates were Western blotted with anti-phospho-IkBa and anti-total IkBa. Endogenous MEKK4 binds to endogenous RIP2 in the unstimulated state. As the NFkB pathway is activated (shown by the anti-phospho-IkBa blot), MEKK4's binding to RIP2 greatly decreases. This pattern is seen in reciprocal coimmunoprecipitations. of p38 ( Figure 3F ). These findings imply that by allowing JNK or p38 activation while inhibiting NFkB, MEKK4 may be an important regulatory point for the coordination of signaling pathways activated downstream of MDP.
Knockdown of MEKK4 Causes Increased NFkB Signaling
For overcoming the limitations of an overexpression system and further establishing the physiological relevance of the sequestration model, MEKK4 expression was inhibited by (C and D) A similar experiment was performed, with the exception that in this set of experiments, MDP (10 mg/mL) was transfected into the cell for stimulation of NOD2. After MDP exposure, NOD2 (C) or MEKK4 (D) was immunoprecipitated, and Western blotting was performed with the indicated antibodies. In the presence of MDP, NOD2 preferentially bound to RIP2 and could compete with MEKK4 for RIP2 binding. (E and F) For determining whether two disease-specific Crohn's-disease-associated NOD2 alleles could compete with MEKK4 for binding to RIP2 in the absence or presence of MDP, two Crohn's-disease-associated NOD2 alleles (L1007insC and D291N) were transfected with MDP (10 mg/mL) and/or HAtagged RIP2 and MEKK4 as indicated. The L1007insC is the mouse homolog, and instead of causing a truncation mutation, it causes a nonsense mutation leading to a 41-nucleotide elongation before truncation (see [13] ). MEKK4 was immunoprecipitated, and Western blotting was performed with the indicated antibodies. Unlike WT NOD2, neither L1007insC NOD2 nor D291N NOD2 could compete with MEKK4 for binding of RIP2 in the presence or absence of MDP. lentiviral shRNA. RAW 264.7 cells were transduced with separate lentiviruses targeting different regions of MEKK4 mRNA. After puromycin selection, clones of each lentivirally transduced population (> 1000) were pooled and assayed for MEKK4 knockdown. Two cell lines (shRNA#3 and shRNA#4) showed decreased MEKK4 expression, compared to vectoronly cells ( Figure 4A ). Clones shRNA#3 and shRNA#4 were treated with MDP for 0, 30, 60, or 90 minutes. Lysates were generated, and half the lysates were subjected to immunoprecipitation with an anti-NEMO antibody under high-stringency conditions (0.25% SDS, 1 M NaCl). Western blotting showed weakly inducible NEMO ubiquitination in the vector-only cell lines; however, when MEKK4 expression was inhibited (shRNA#3 and shRNA#4), not only was the basal NEMO ubiquitination (time 0) increased, but the inducible NEMO ubiquitination was also increased ( Figure 4A ). This effect mirrored NFkB activity because, as shown in the phospho-Ikba blot, cell lines shRNA#3 and shRNA#4 show both increased basal phospho-IkBa and increased inducible phospho-IkBa when compared to vector-only cells ( Figure 4A ). Interestingly, total IkBa was increased in both MEKK4-knockdown cell lines. Because IkBa is transcriptionally regulated by NFkB [19] , this could also indicate an increased basal NFkB activity in these cell lines. JNK activation showed relatively similar activation kinetics between vector-only cells and MEKK4-knockdown cells; however, p38 activation was undetectable in the MEKK4-knockdown cells ( Figure 4A ). For then determining the effect of this altered cellular signaling on cytokine production in the MEKK4-knockdown cells, basal production levels of a variety of cytokines were measured. IL-6, IL-10, IL-12, TNFa, and G-CSF levels were all significantly increased in the unstimulated MEKK4-knockdown macrophages ( Figure 4B ). Lastly, expression of MDP-inducible genes was then assayed. Both RIP2 and A20 were significantly increased both in the basal state and upon MDP induction in the MEKK4-knockdown macrophages, whereas another innate immune mediator, IRAK4, which is not inducible by MDP, was unaltered in the MEKK4-knockdown cells ( Figure 4C ). These results suggest that the MEKK4-knockdown cells may show increased basal activation of the NOD2 pathway. Because recent data suggest that chronic MDP stimulation causes hyporesponsiveness to Tolllike Receptor (TLR) agonists [20, 21] , the response of the MEKK4-knockdown cells to TLR2 and TLR4 agonists was then assayed. Unlike MDP, these cells were hyporesponsive to both Pam 3 Cys 4 (TLR2 agonist) and LPS (TLR4 agonist) (Figures S4A and S4B ). In addition, synergy between MDP and these agonists was lost ( Figure S4B ). Lastly, these cells showed an inability to fully respond to M. Tuberculosis infection ( Figure S5 ), an infection in which both TLR2 and NOD2 agonists are present [22] . In sum, these findings support the model that MEKK4 acts to limit NOD2:RIP2-induced NFkB activation and specifies innate immunological signaltransduction mechanisms.
Discussion
In this work, we have identified a mechanism by which basal activity of the NOD2:RIP2 complex and signal-transduction specificity downstream of this complex can be controlled. We identified the MAP3K, MEKK4, as a binding partner of RIP2 (Figure 1 ) and showed that MEKK4 could inhibit RIP2-induced NEMO ubiquitination and IKK activation (Figure 3 ). This inhibition was specific to the NFkB pathway, given that RIP2-induced JNK activation was unaffected by MEKK4 expression (Figures 3 and 4) . We showed biochemically that endogenous RIP2 binds to MEKK4. Upon exposure to the NOD2 agonist, MDP, RIP2 dissociates from MEKK4 and binds to NOD2, such that NFkB activation can be achieved (Figures  1-3 ). Crohn's-disease-associated polymorphisms of NOD2 cannot compete with MEKK4 for RIP2 binding ( Figure 2F) , and inhibition of MEKK4 expression causes increased MDP-induced NEMO ubiquitination, increased MDP-induced NFkB activation, and increased basal cytokine production (Figure 4) . This work has implications both for gastrointestinal mucosal immunology and for the molecular pathophysiology of Crohn's disease. NFkB's role in gastrointestinal inflammation has been confusing. Many Crohn's disease patients show too much NFkB activation, and agents aimed at disrupting TNF-driven NFkB activity can be efficacious in treating some of these patients [1, 3] . However, recent mouse work suggests that physiologic NFkB activity may be protective against chronic GI inflammation, helping to blunt the immune response under normal circumstances of no inflammation [23] . Likewise, the role of NFkB in NOD2-driven Crohn's disease has been confusing. The Crohn's-disease-susceptibility gene, CARD15, shows autosomal-recessive genetics, with the Crohn's-disease-associated NOD2 polymorphisms showing loss of function at NFkB [3, 5, 6] . Anti-TNF agents are no more efficacious in NOD2-driven Crohn's disease [24] , and NOD2-knockout mice show no increased intestinal inflammation unless they are manipulated [15, 25] . In contrast, a knockin mouse containing the most common loss-of-function Crohn's-disease-associated NOD2 allele shows the opposite result, that of increased intestinal inflammation [26] . These disparate findings could be explained in part by the fact that, rather than simply driving a cytokine response to a pathogenic intracellular bacteria, NOD2 helps to coordinate cytokine release between various signaling pathways and by the fact that NOD2 helps to establish protective, physiologic NFkB activity. These two explanations may help explain why Crohn's-disease-associated NOD2 polymorphisms predispose one to the development of Crohn's disease. The Crohn's-disease-associated NOD2 polymorphisms may not properly couple signaling pathways to coordinate cytokine release under inflammatory conditions, whereas under noninflamed conditions, they do not allow protective physiologic NFkB activation. This manuscript supports this hypothesis and suggests that the level of control of this process lies at the MAP3Ks.
This work suggests that the MAP3Ks (specifically TAK1 [7] [8] [9] and MEKK4) coordinate disparate NOD2:RIP2-induced NFkB and p38 activation. This possibility is concordant with the MEKK4-knockout mouse. Although efforts to characterize this mouse are complicated by perinatal lethality due to failure of neural-tube closure, signaling characterization of both MEKK4 2/2 MEFs [27, 28] and MEKK4 2/2 T cells [29] shows defective p38 activation, similar to the effects we obtained in MEKK4-knockdown macrophages. In our hands, MEKK4 knockdown also gave an MDP response similar to that seen in CARD9
2/2 cells (lack of p38 signaling, with intact NFkB signaling [30] ), and it will be important that future studies determine whether MEKK4 and CARD9 interact in a signaling pathway to help coordinate NOD2 signaling responses in Crohn's disease.
Conclusions
Because the lumen of the GI tract contains both probiotic and potentially pathogenic organisms, the normal mucosal surface is, therefore, constantly exposed to PAMPs. There must be mechanisms in place for dampening of proinflammatory NFkB responses, and our work suggests that by sequestering RIP2, MEKK4 plays a key role in dampening basal NFkB activity. However, upon pathogen exposure, NFkB activation must be rapid and the signal transduction mechanisms precise in order to establish proper cytokine release for eradication of the offending organism. Given the molecular genetics of both NOD2 polymorphic patients and various NOD2-deficient mice, NOD2 may play a central role in both the basal NFkB response to nonpathogenic bacterial flora and the NFkB response and cytokine-coordination response to pathogenic bacteria. Our work suggests that MEKK4 helps control both of these NOD2-driven responses and begins to serve as a framework by which to study NOD2-driven signalingpathway crosstalk.
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(F) Flag-tagged p38 was transfected into 293 cells with RIP2 and/or MEKK4. After immunoprecipitation with the Flag antibody, Western blots were performed. MEKK4 strongly activates p38. RIP2 coexpression has little effect on this activation. As a control, an empty lentivirus was used. Western blotting was performed for determining the degree of inhibition of MEKK4 expression. Cell lines MEKK4 shRNA #3 and MEKK4 shRNA #4 showed the greatest loss of expression and were used for subsequent experiments. These cell lines were then exposed to MDP for 0, 30, 60, or 90 minutes. Lysates were generated, and half the lysates were subjected to immunoprecipitation under stringent washing conditions (0.25% SDS, 1 M NaCl). Western blots showed that NEMO ubiquitination was increased basally and was greatly increased under stimulation in the shRNA#3 and shRNA#4 cell lines but not in the vector-only cell line. In agreement with this finding, phospho-IkBa was increased in these cell lines (both basally and with stimulation), indicating higher NFkB activity. In contrast, whereas JNK signaling was similar between the vector-only cell line and the shRNA#3 and the shRNA#4 cell lines, p38 signaling was greatly decreased when MEKK4 expression was inhibited. (B) For determining whether this increased basal NFkB activation resulted in altered cytokine production, cytokine levels were assayed from these cell lines by ELISA. IL-6, IL-10, IL-12, TNFa, and G-CSF were all significantly basally upregulated in both MEKK4-knockdown lines. Student's t test showed that IL-6, IL-10, TNF, and G-CSF increases had a significance of p < 0.05 (indicated by an asterisk). Given that these cytokines are all regulated by NFkB, these findings suggest a functional role for the increased NFkB signaling seen in Figure 4A . Error bars are SEM (standard error of the mean) based on triplicate experiments. (C) Expression of two NFkB-regulated proteins was then assayed either under basal conditions or after overnight MDP stimulation. Both RIP2 and A20 were significantly upregulated in the MEKK4-knockdown lines. In contrast, the innate immunity protein, IRAK4, whose expression is not regulated by NFkB activity, was essentially unchanged.
